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1. INTRODUCTION {#ccr32676-sec-0001}
===============

Perivascular epithelioid cell tumors (PEComas) are a family of rare mesenchymal neoplasms that show a perivascular tumor epithelioid cell (PEC) differentiation. This group of tumors includes angiomyolipoma, clear cell "sugar" tumor (CCST) of the lung and extrapulmonary sites, clear cell myomelanocytic tumor of the falciform ligament, and lymphangioleiomyoma. Perivascular epithelioid cell tumors have distinct histologic features such as epithelioid to spindle cell appearance with clear to granular eosinophilic cytoplasm and round to oval nucleus with inconspicuous nucleoli. Immunohistochemically, this family of tumors characteristically shows markers of PEC differentiation including myogenic and melanocytic markers. Perivascular epithelioid cell tumors have previously been associated with tuberous sclerosis,[1](#ccr32676-bib-0001){ref-type="ref"} although they have been reported to occur in the absence of this syndrome.[2](#ccr32676-bib-0002){ref-type="ref"} Perivascular epithelioid cell tumors are typically benign but are known to recur,[3](#ccr32676-bib-0003){ref-type="ref"} and malignant behavior has been reported from a number of primary sites.[4](#ccr32676-bib-0004){ref-type="ref"} Commonly reported sites of origin include abdominal and gynecologic soft tissue,[5](#ccr32676-bib-0005){ref-type="ref"} although cases in the head and neck region have been previously described.[6](#ccr32676-bib-0006){ref-type="ref"} Here, we describe the first reported case of PEComa of the pterygopalatine fossa.

2. CASE {#ccr32676-sec-0002}
=======

A 78‐year‐old woman was transferred to our hospital for management of a left occipital intracerebral hemorrhage. A follow‐up MRI incidentally revealed a T2 hypointense, T1 isointense left pterygopalatine fossa/retroantral region mass with postcontrast enhancement measuring 16 × 7 mm (Figures [1](#ccr32676-fig-0001){ref-type="fig"} and [2](#ccr32676-fig-0002){ref-type="fig"}). The mass was noted to have enlarged since a CTA obtained 4 months prior, where the mass was noted in retrospect. The lesion was approached via an endoscopic, endonasal transmaxillary approach using navigation with excisional biopsy resection. During this procedure, the inferior turbinate was left intact, the middle turbinate was medialized for uncinectomy, the maxillary ostium was opened, ethmoid bulla was removed, posterior maxillary wall was resected, and internal maxillary artery was clipped to provide adequate hemostasis. Tumor specimen was sent for frozen section, which returned as chronically inflamed polypoid tissue. Due to the apparent benign nature of the mass, the tumor was simply debulked, forgoing further dissection superiorly to the inferior orbital fissure. Microscopic examination revealed an organizing hematoma surrounded by sheets of spindle‐shaped cells with eosinophilic cytoplasm and oval nuclei with small nucleoli and low mitotic count (Figure [3](#ccr32676-fig-0003){ref-type="fig"}A,B). A panel of immunohistochemical stains was performed that revealed positivity only for HMB45 and smooth muscle actin. This distinct immunohistochemical profile is suggestive of PEC differentiation. In addition, negative in situ hybridization for EWS and TFE3 was supportive of the diagnosis of conventional PEComa. She did not have a personal or family history of tuberous sclerosis. Head and neck tumor board recommended serial imaging given her medical comorbidities, with possible radiation therapy if significant progression was noted. She died 3 months later from complications of her intracerebral hemorrhage.

![T1 postcontrast axial MRI. Arrow points to the mass lesion. A represents the lateral pterygoid muscle. B represents the pterygoid plate](CCR3-8-553-g001){#ccr32676-fig-0001}

![T1 postcontrast coronal MRI. Arrow points to the mass lesion](CCR3-8-553-g002){#ccr32676-fig-0002}

![A, Organizing hematoma (arrow) surrounded by sheets of low‐grade spindle cell proliferation with variable cellularity (200×, H&E). B, Bland spindle cells with eosinophilic cytoplasm and oval nuclei with small nucleoli in the absence of significant mitosis (400×, H&E)](CCR3-8-553-g003){#ccr32676-fig-0003}

3. DISCUSSION {#ccr32676-sec-0003}
=============

Pterygopalatine fossa masses are rare and have a broad differential diagnosis including epidermoid cyst, meningocele, mucosal carcinoma, schwannoma, chordoma, teratoma, and neurofibroma.[7](#ccr32676-bib-0007){ref-type="ref"} The majority of these masses are benign in nature, although they can be locally invasive. The workup of pterygopalatine fossa lesions generally consists of nasal endoscopy, CT scan, and contrast‐enhanced MRI. Biopsy is indicated to rule out malignancy except in the case of suspected juvenile nasopharyngeal angiofibroma, and the decision to radically resect can be made based on tumor histology.[8](#ccr32676-bib-0008){ref-type="ref"} PEComas typically exhibit benign behavior although they have been reported to metastasize, most commonly to cutaneous sites,[4](#ccr32676-bib-0004){ref-type="ref"}, [9](#ccr32676-bib-0009){ref-type="ref"} although Tynski et al reported a case of PEComa metastasis to the orbit.[10](#ccr32676-bib-0010){ref-type="ref"} Our literature review found 43 reported cases of PEComa of the head and neck; however, most were cutaneous in the nasal cavity or in the orbit (Table [1](#ccr32676-tbl-0001){ref-type="table"}). Only one case of skull base PEComa has been reported, and there are no previously reported cases of this pathology in the pterygopalatine fossa. The case of posterior skull base PEComa reported by Lehman involved a tumor with histologic evidence of malignancy that had extensive local invasion of the petrous/occipital bones, clivus, and foramen magnum as well as eventual metastasis to the lung and spine resulting in the patient\'s demise.[11](#ccr32676-bib-0011){ref-type="ref"} Our case of PEComa of the pterygopalatine fossa did not display signs of malignancy histologically or clinically, although long‐term surveillance was not possible due to the patient\'s unrelated death shortly after diagnosis. Management of these tumors generally consists of resection alone due to their benign behavior although observation is a reasonable option depending upon the location of the tumor and resulting signs/symptoms, evidence of malignant behavior, and patient comorbidities. Radiation therapy has also been used with some success,[12](#ccr32676-bib-0012){ref-type="ref"} but there is no established indication for adjuvant radiation.[6](#ccr32676-bib-0006){ref-type="ref"}

###### 

Literature review of PEComa of the Head and Neck. A review of the literature was performed with a Pubmed search of the terms "PEComa" and "head and neck."

  Author (Year)                                                       Location                  Age/Gender      Treatment                                                  Outcome
  ------------------------------------------------------------------- ------------------------- --------------- ---------------------------------------------------------- --------------------------------------------------------------
  Lehman (2004)[11](#ccr32676-bib-0011){ref-type="ref"}               Posterior skull base      49‐y‐o female   Partial resection                                          Metastasis to lung and spine, death
  Weindling et al (2015)[13](#ccr32676-bib-0013){ref-type="ref"}      Maxillary sinus           78‐y‐o male     NR                                                         NR
  Leavers et al (2012)[14](#ccr32676-bib-0014){ref-type="ref"}        Maxillary nasal process   74‐y‐o female   Resection                                                  No recurrent disease
  Banerjee et al (2001)[15](#ccr32676-bib-0015){ref-type="ref"}       Nasal cavity              34‐y‐o female   Resection                                                  No recurrent disease
  Kuroda et al (2009)[16](#ccr32676-bib-0016){ref-type="ref"}         Nasal cavity              79‐y‐o male     NR                                                         NR
  Afrogheh et al (2013)[17](#ccr32676-bib-0017){ref-type="ref"}       Nasal cavity              19‐y‐o female   Resection                                                  No recurrent disease
  Bocciolini et al (2013)[18](#ccr32676-bib-0018){ref-type="ref"}     Nasal cavity              40‐y‐o female   Resection                                                  No recurrent disease
  Panelos et al (2009)[19](#ccr32676-bib-0019){ref-type="ref"}        Nasal septum              50‐y‐o female   Resection                                                  No recurrent disease
  Erkilic et al (2005)[20](#ccr32676-bib-0020){ref-type="ref"}        Nasal cavity              52‐y‐o male     Resection                                                  NR
  Iwata et al (2013)[21](#ccr32676-bib-0021){ref-type="ref"}          Nasal cavity              60‐y‐o male     Resection                                                  NR
  Moreira et al (2011)[22](#ccr32676-bib-0022){ref-type="ref"}        Nasal cavity              54‐y‐o male     Resection                                                  No recurrent disease
  Tardio et al (2002)[23](#ccr32676-bib-0023){ref-type="ref"}         Nasal cavity              45‐y‐o male     Resection                                                  No recurrent disease
  Gatalica et al (1994)[24](#ccr32676-bib-0024){ref-type="ref"}       Nasal cavity              64‐y‐o male     NR                                                         NR
  Watanabe et al (1999)[25](#ccr32676-bib-0025){ref-type="ref"}       Nasal cavity              66‐y‐o male     Resection                                                  No recurrent disease
  Watanabe et al (1999)[25](#ccr32676-bib-0025){ref-type="ref"}       Nasal cavity              88‐y‐o female   Resection                                                  No recurrent disease
  Dawlatly et al (1988)[26](#ccr32676-bib-0026){ref-type="ref"}       Nasal cavity              52‐y‐o male     NR                                                         No recurrent disease
  Gana et al (2012)[2](#ccr32676-bib-0002){ref-type="ref"}            Nasal cavity              22‐y‐o female   Resection (positive margins), re‐resection                 No recurrent disease
  McGregor et al (2017)[27](#ccr32676-bib-0027){ref-type="ref"}       Nasal cavity              54‐y‐o female   Resection                                                  No recurrent disease
  Bandhlish et al (2011)[6](#ccr32676-bib-0006){ref-type="ref"}       Nasal cavity              18‐y‐o female   Embolization, resection (positive margins), re‐resection   No recurrent disease
  Bandhlish et al (2011)[6](#ccr32676-bib-0006){ref-type="ref"}       Nasal cavity              71‐y‐o female   NR                                                         NR
  Bandhlish et al (2011)[6](#ccr32676-bib-0006){ref-type="ref"}       Glottis                   26‐y‐o female   Resection                                                  No recurrent disease
  Huai‐yin et al (2009)[28](#ccr32676-bib-0028){ref-type="ref"}       Glottis                   38‐y‐o female   Resection                                                  Re‐resection for recurrence at 15 mo, no evidence of disease
  Huai‐yin et al (2009)[28](#ccr32676-bib-0028){ref-type="ref"}       Laryngeal vestibule       42‐y‐o male     Resection                                                  No recurrent disease
  Huai‐yin et al (2009)[28](#ccr32676-bib-0028){ref-type="ref"}       Hypopharynx               47‐y‐o male     Resection                                                  No recurrent disease
  Koutlas et al (2005)[29](#ccr32676-bib-0029){ref-type="ref"}        Hard palate               46‐y‐o female   Resection                                                  No recurrent disease
  Saluja et al (2018)[12](#ccr32676-bib-0012){ref-type="ref"}         Oropharynx                28‐y‐o female   Resection, everolimus, radiation                           No recurrent disease
  Foschini et al (1999)[30](#ccr32676-bib-0030){ref-type="ref"}       Parotid                   68‐y‐o female   Resection                                                  No recurrent disease
  Ghazali et al (2010)[31](#ccr32676-bib-0031){ref-type="ref"}        Cheek                     32‐y‐o female   Resection                                                  No recurrent disease
  Greveling et al (2013)[32](#ccr32676-bib-0032){ref-type="ref"}      Cheek                     44‐y‐o male     Resection (positive margins), re‐resection, radiation      No recurrent disease
  Girardi et al (2018)[33](#ccr32676-bib-0033){ref-type="ref"}        Cheek                     69‐y‐o male     Resection, radiation                                       No recurrent disease
  Calder et al (2008)[34](#ccr32676-bib-0034){ref-type="ref"}         Scalp                     76‐y‐o male     Resection                                                  No recurrent disease
  Argani et al (2010)[35](#ccr32676-bib-0035){ref-type="ref"}         Scalp                     80‐y‐o male     NR                                                         NR
  Folpe et al (2005)[5](#ccr32676-bib-0005){ref-type="ref"}           Scalp                     80‐y‐o male     Resection                                                  Lost to follow‐up
  Folpe et al (2005)[5](#ccr32676-bib-0005){ref-type="ref"}           Neck                      77‐y‐o female   Resection, re‐resection, radiation                         No recurrent disease
  Iyengar et al (2004)[36](#ccr32676-bib-0036){ref-type="ref"}        Orbit                     9‐y‐o female    NR                                                         NR
  Paliogiannis et al (2016)[37](#ccr32676-bib-0037){ref-type="ref"}   Orbit                     46‐y‐o male     Resection                                                  No recurrent disease
  Nair et al (2018)[38](#ccr32676-bib-0038){ref-type="ref"}           Orbit                     9‐y‐o female    Resection                                                  No recurrent disease
  Lubo et al (2016)[39](#ccr32676-bib-0039){ref-type="ref"}           Orbit                     47‐y‐o male     Resection                                                  No recurrent disease
  Guthoff et al (2008)[40](#ccr32676-bib-0040){ref-type="ref"}        Orbit                     54‐y‐o male     Resection                                                  No recurrent disease
  Alam et al (2017)[41](#ccr32676-bib-0041){ref-type="ref"}           Orbit                     5‐y‐o male      Resection, Chemotherapy                                    No recurrent disease
  Furusato et al (2010)[42](#ccr32676-bib-0042){ref-type="ref"}       Eyelid                    26‐y‐o female   Excisional biopsy, re‐excision                             No recurrent disease
  Furusato et al (2010)[42](#ccr32676-bib-0042){ref-type="ref"}       Ciliary body              7‐y‐o male      Resection                                                  No recurrent disease
  Goto et al (2015)[43](#ccr32676-bib-0043){ref-type="ref"}           Ciliary body              13‐y‐o female   Resection                                                  No recurrent disease
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